메뉴 건너뛰기




Volumn 56, Issue 1, 2005, Pages 251-252

Hyperproduction of AmpC β-lactamase in a clinical isolate of Escherichia coli associated with a 30 bp deletion in the attenuator region of ampC [2]

Author keywords

AmpC; Antimicrobial resistance; E. coli; Mutations

Indexed keywords

ADENINE; BACTERIAL DNA; BETA LACTAMASE; BETA LACTAMASE INHIBITOR; CEFOTAXIME; CEFTAZIDIME; CEPHALOSPORIN DERIVATIVE; CEPHAMYCIN DERIVATIVE; CLAVULANIC ACID; CYTOSINE; GUANINE; PENICILLIN DERIVATIVE; THYMINE; AMPC BETA LACTAMASES; AMPC BETA-LACTAMASES; BACTERIAL PROTEIN;

EID: 24044497284     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dki149     Document Type: Letter
Times cited : (7)

References (6)
  • 1
    • 0344359737 scopus 로고    scopus 로고
    • Molecular basis of AmpC hyperproduction in clinical isolates of Escherichia coli
    • Nelson EC, Elisha BG. Molecular basis of AmpC hyperproduction in clinical isolates of [i#Escherichia coli. Antimicrob Agents Chemother#1i] 1999; [b#43#1b]: 957-9.
    • (1999) Antimicrob. Agents Chemother. , vol.43 , pp. 957-959
    • Nelson, E.C.1    Elisha, B.G.2
  • 2
    • 0033836292 scopus 로고    scopus 로고
    • Activities of imipenem and cephalosporins against clonally related strains of Escherichia coli hyperproducing chromosomal β-lactamase and showing altered porin profiles
    • Martínez-Martínez L, Conejo MC, Pascual A [i#et al.#1i] Activities of imipenem and cephalosporins against clonally related strains of [i#Escherichia coli#1i] hyperproducing chromosomal β-lactamase and showing altered porin profiles. [i#Antimicrob Agents Chemother#1i] 2000; [b#44#1b] 2534-6.
    • (2000) Antimicrob. Agents Chemother. , vol.44 , pp. 2534-2536
    • Martínez-Martínez, L.1    Conejo, M.C.2    Pascual, A.3
  • 3
    • 0034129458 scopus 로고    scopus 로고
    • Analysis of the effects of -42 and -32 ampC promoter mutations in clinical isolates of Escherichia coli hyperproducing AmpC
    • Caroff N, Espaze E, Gautreau D [i#et al.#1i] Analysis of the effects of -42 and -32 [i#ampC#1i] promoter mutations in clinical isolates of [i#Escherichia coli#1i] hyperproducing AmpC. [i#J Antimicrob Chemother#1i] 2000; [b#45#1b]: 783-8.
    • (2000) J. Antimicrob. Chemother. , vol.45 , pp. 783-788
    • Caroff, N.1    Espaze, E.2    Gautreau, D.3
  • 4
    • 0038338397 scopus 로고    scopus 로고
    • High-level expression of AmpC β-lactamase due to insertion of nucleotides between -10 and -35 promoter sequences in Escherichia coli clinical isolates: Cases not responsive to extended-spectrum-cephalosporin treatment
    • Siu LK, Lu PL, Chen JY [i#et al.#1i] High-level expression of AmpC β-lactamase due to insertion of nucleotides between -10 and -35 promoter sequences in [i#Escherichia coli#1i] clinical isolates: Cases not responsive to extended-spectrum-cephalosporin treatment. [i#Antimicrob Agents Chemother#1i] 2003; [b#47#1b]: 2138-44.
    • (2003) Antimicrob. Agents Chemother. , vol.47 , pp. 2138-2144
    • Siu, L.K.1    Lu, P.L.2    Chen, J.Y.3
  • 5
    • 0034783627 scopus 로고    scopus 로고
    • Molecular mechanisms of cefoxitin resistance in Escherichia coli from the Toronto area hospitals
    • Forward KR, Willey BM, Low DE [i#et al.#1i] Molecular mechanisms of cefoxitin resistance in [i#Escherichia coli#1i] from the Toronto area hospitals. [i#Diagn Microbiol Infect Dis#1i] 2001; [b#41#1b]: 57-63.
    • (2001) Diagn. Microbiol. Infect. Dis. , vol.41 , pp. 57-63
    • Forward, K.R.1    Willey, B.M.2    Low, D.E.3
  • 6
    • 0141643241 scopus 로고    scopus 로고
    • Cephamycin resistance in clinical isolates and laboratory-derived strains of Escherichia coli, Nova Scotia, Canada
    • Clarke B, Hiltz M, Musgrave H [i#et al.#1i] Cephamycin resistance in clinical isolates and laboratory-derived strains of [i#Escherichia coli#1i] Nova Scotia, Canada. [i#Emerg Infect Dis#1i] 2003; [b#9#1b]: 1254-9.
    • (2003) Emerg. Infect. Dis. , vol.9 , pp. 1254-1259
    • Clarke, B.1    Hiltz, M.2    Musgrave, H.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.